Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01151384 · ClinicalTrials.gov registry record · Phase 1
Liposome Encapsulated Docetaxel (LE-DT) in Patients With Solid Tumors
A Phase 1 study, sponsored by INSYS Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT01151384 is a Phase 1 study that has completed, run by INSYS Therapeutics. The registered enrollment target is 30 participants.
The verdict
NCT01151384, a Phase 1 study, has completed, sponsored by INSYS Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Liposome Encapsulated Docetaxel (LE-DT) is a novel proprietary delivery system of docetaxel developed by NeoPharm, Inc. In this Phase I study, the LE-DT was evaluated for the maximum tolerated dose and dose limiting toxicity (DLT) in patients with advance solid tumors. It was also evaluated for pharmacokinetic and anti-tumor effects.
Interventions
- DRUG LE-DT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-02 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01151384
The ClinicalTrials.gov registry entry for NCT01151384 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is INSYS Therapeutics, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LE-DT is the first listed.
NCT01151384 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01151384 about?
NCT01151384 is a clinical study titled "Liposome Encapsulated Docetaxel (LE-DT) in Patients With Solid Tumors". Liposome Encapsulated Docetaxel (LE-DT) is a novel proprietary delivery system of docetaxel developed by NeoPharm, Inc. In this Phase I study, the LE-DT was evaluated for the maximum tolerated dose and dose limiting toxicity (DLT) in patients with advance solid tumors. It was also evaluated for phar...
What is the current status of trial NCT01151384?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2008-02. Estimated completion is 2010-05.
What interventions are being tested in trial NCT01151384?
The interventions under investigation include: LE-DT (DRUG).
Who is sponsoring clinical trial NCT01151384?
This trial is sponsored by INSYS Therapeutics, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.